Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Mar 25;13:975–990. doi: 10.2147/DDDT.S195412

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Ye et al. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

Inhibition of pyroptosis by emodin involved the TLR4/MyD88/NF-κB/NLRP3 inflammasome pathway.

Notes: (A) Representative Western blot luminogram of TLR4, MyD88, NLRP3, ASC, p-p65, and p-IκBα among the control, H/R, H/R+Emodin (2.5 µM), H/R+Emodin (5 µM), and H/R+Emodin (10 µM) groups. Cells in normoxic conditions were defined as the control (B). Protein semiquantification is shown for TLR4 and MyD88 based on the results of 5A. (C) Protein semiquantification is shown for NLRP3 and ASC based on the results of 5A. (D) Protein semiquantification is shown for p-p65 and p-IκBα based on the results of 5A. (E) Concentrations of IL-1β in cell culture supernatants were detected by ELISA. (F) Representative Western blot luminogram of GSDMD-FL and GSDMD-N among the control, H/R, H/R+DMSO, H/R+NLRP3 inflammasome inhibitor (10 µM), and H/R+Bay-117082 (5 µM) groups. (G) Protein semiquantification is shown for GSDMD-FL and GSDMD-N based on the results of 5F. Bay-117082, NF-κB pathway inhibitor. p-p65 was standardized by p65, and p-IκBα was standardized by IκBα. The expression of other proteins was standardized by GAPDH. Data are expressed as the mean ± SD. *P<0.05 vs the control group, ^#P<0.05 vs the H/R group.

Abbreviations: H/R, hypoxia/reoxygenation; DMSO, dimethyl sulfoxide; ns, not significant.

Inhibition of pyroptosis by emodin involved the TLR4/MyD88/NF-κB/NLRP3 inflammasome pathway.

Notes: (A) Representative Western blot luminogram of TLR4, MyD88, NLRP3, ASC, p-p65, and p-IκBα among the control, H/R, H/R+Emodin (2.5 µM), H/R+Emodin (5 µM), and H/R+Emodin (10 µM) groups. Cells in normoxic conditions were defined as the control (B). Protein semiquantification is shown for TLR4 and MyD88 based on the results of 5A. (C) Protein semiquantification is shown for NLRP3 and ASC based on the results of 5A. (D) Protein semiquantification is shown for p-p65 and p-IκBα based on the results of 5A. (E) Concentrations of IL-1β in cell culture supernatants were detected by ELISA. (F) Representative Western blot luminogram of GSDMD-FL and GSDMD-N among the control, H/R, H/R+DMSO, H/R+NLRP3 inflammasome inhibitor (10 µM), and H/R+Bay-117082 (5 µM) groups. (G) Protein semiquantification is shown for GSDMD-FL and GSDMD-N based on the results of 5F. Bay-117082, NF-κB pathway inhibitor. p-p65 was standardized by p65, and p-IκBα was standardized by IκBα. The expression of other proteins was standardized by GAPDH. Data are expressed as the mean ± SD. *P<0.05 vs the control group, ^#P<0.05 vs the H/R group.

Abbreviations: H/R, hypoxia/reoxygenation; DMSO, dimethyl sulfoxide; ns, not significant.